

Nobuo Okabe,\* Toshihiko  
 Aziyama and Mamiko Odoko

Faculty of Pharmaceutical Sciences, Kinki  
 University, Kowakae 3-4-1, Higashiosaka,  
 Osaka 577-8502, Japan

Correspondence e-mail:  
 okabe@phar.kindai.ac.jp

Key indicators

Single-crystal X-ray study  
 T = 296 K  
 Mean  $\sigma(\text{C}-\text{C}) = 0.005 \text{ \AA}$   
 R factor = 0.032  
 wR factor = 0.089  
 Data-to-parameter ratio = 16.3

For details of how these key indicators were  
 automatically derived from the article, see  
<http://journals.iucr.org/e>.


(1,2-Benzenediolato- $\kappa^2\text{O},\text{O}'$ )(2,2'-biquinoline- $\kappa^2\text{N},\text{N}'$ )-  
 palladium(II)

In the title complex,  $[\text{Pd}(\text{C}_6\text{H}_4\text{O}_2)(\text{C}_{18}\text{H}_{12}\text{N}_2)]$ , the central Pd atom has a distorted *cis*-planar four-coordination geometry defined by two O atoms of a 1,2-benzenediolate dianion and two N atoms of a 2,2'-biquinoline ligand. The overall structure of the complex is not planar, with a dihedral angle of  $136.23(8)^\circ$  between the quinoline and benzenediolate mean planes.

Received 21 September 2005  
 Accepted 26 September 2005  
 Online 30 September 2005


Comment

A large number of investigations have focused on the design of palladium(II) or platinum(II) complexes because of their biological significance in areas such as antitumor, antimicrobial and antiviral activity (Corbi *et al.*, 2005; Giovagnini *et al.*, 2005).



Palladium complexes with aromatic ligands and *cis*-square planar coordination geometry have been intensively studied because of their cytotoxic activity (Mansuri-Torshizi *et al.*, 2001; Afrasiabi *et al.*, 2004; Rebolledo *et al.*, 2005; Padhye *et al.*, 2005) or DNA binding properties (Cusumano & Giannetto, 1997; Tercero *et al.*, 2003); such binding is the principal target in the chemotherapy of tumors (Shehata, 2001; Cusumano & Giannetto, 1997; Neidle *et al.*, 1987).

As an extension of these studies, we have synthesized and determined the crystal structures of a number of *cis*-coordinated palladium complexes with aromatic ligands including Pd(bpy)(cbdca) and Pb(phen)(cbdca) (Muranishi & Okabe, 2004), Pd(phen)(ca) (Okabe *et al.*, 2003), Pd(bpy)(nad) and Pd(biq)(nad) (Okabe *et al.*, 2004) and Pd(bpy)(ca) (Okabe *et al.*, 2005), where bpy is 2,2'-bipyridine, cbdca is 1,1-cyclobutanedicarboxylate, phen is 1,10-phenanthroline, nad is 2,3-naphthalenediolate, biq is biquinoline and ca is catecholate or 1,2-benzenediolate.



**Figure 1**  
The molecular structure of (I), showing 50% displacement ellipsoids for the non-H atoms.

In this study, the title compound, Pd(biq)(ca), (I), has been synthesized and its structure determined. In complex (I), the central Pd atom has a distorted *cis*-square-planar coordination geometry arising from the two N atoms of biq and the two O atoms of ca (Fig. 1).

The overall structure is not planar and resembles that of Pd(biq)(nad), (II) (Okabe *et al.*, 2004), which has the same biq ligand as (I) and two analogous anionic O atoms of the 2,3-naphthalenediolate ligand. The dihedral angle between the biq and ca mean planes in (I) is 136.23 (8)°, with a corresponding value for (II) of 148.73 (7)° (where a dihedral angle of 180° indicates a flat structure). This shows that the distortion of (I) from the planar conformation is larger than in (II).

The Pd–X (X = N, O) bond lengths and angles in (I) are similar to those of (II) (Table 1). This resemblance suggests similar coordination bond strength in both complexes.

## Experimental

Firstly, biq (5.0 mg dissolved in 2 ml dimethylformamide, DMF) was reacted with palladium acetate, Pd(CH<sub>3</sub>COOH)<sub>2</sub> (4.4 mg in 2 ml DMF) for 15 min at room temperature (molar ratio of 1:1). An equimolar amount of caH<sub>2</sub> dissolved in DMF was then added with stirring. This mixture was left to stand at room temperature and yielded blue block-shaped crystals of (I) over a period of days.

### Crystal data

[Pd(C<sub>6</sub>H<sub>4</sub>O<sub>2</sub>)(C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>)]  
*M<sub>r</sub>* = 470.81  
 Monoclinic, *P*2<sub>1</sub>/*c*  
*a* = 11.042 (2) Å  
*b* = 9.487 (2) Å  
*c* = 17.796 (2) Å  
 $\beta$  = 95.635 (10)°  
*V* = 1855.2 (6) Å<sup>3</sup>  
*Z* = 4

*D<sub>x</sub>* = 1.686 Mg m<sup>-3</sup>  
 Mo *K*α radiation  
 Cell parameters from 25 reflections  
 $\theta$  = 14.4–15.0°  
 $\mu$  = 1.02 mm<sup>-1</sup>  
*T* = 296.2 K  
 Plate, blue  
 0.20 × 0.15 × 0.10 mm

### Data collection

Rigaku AFC-5R diffractometer  
 $\omega$ -2 $\theta$  scans  
 Absorption correction:  $\psi$  scan  
 (North *et al.*, 1968)  
*T*<sub>min</sub> = 0.832, *T*<sub>max</sub> = 0.903  
 4749 measured reflections  
 4267 independent reflections  
 2996 reflections with *I* > 2σ(*I*)

*R*<sub>int</sub> = 0.043  
 $\theta$ <sub>max</sub> = 27.5°  
*h* = 0 → 14  
*k* = 0 → 12  
*l* = -23 → 23  
 3 standard reflections  
 every 150 reflections  
 intensity decay: 0.4%

### Refinement

Refinement on *F*<sup>2</sup>  
*R* [*F*<sup>2</sup> > 2σ(*F*<sup>2</sup>)] = 0.032  
*wR* (*F*<sup>2</sup>) = 0.089  
*S* = 1.07  
 4267 reflections  
 262 parameters

H-atom parameters constrained  
 $w = 1/[\sigma^2(F_o^2) + (0.0349P)^2]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\max} = 0.002$   
 $\Delta\rho_{\max} = 0.47 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\min} = -0.35 \text{ e \AA}^{-3}$

**Table 1**

Comparative selected geometric parameters (Å, °).

	(I)	(II) <sup>i</sup>
Pd1–O1	1.987 (2)	1.992 (4)
Pd1–O2	1.990 (2)	1.982 (4)
Pd1–N1	2.055 (3)	2.039 (4)
Pd1–N2	2.047 (2)	2.037 (4)
O1–Pd1–O2	83.19 (9)	83.6 (2)
O1–Pd1–N1	98.19 (10)	98.4 (2)
O1–Pd1–N2	173.8 (1)	171.1 (2)
O2–Pd1–N1	172.1 (1)	174.4 (2)
O2–Pd1–N2	97.49 (10)	97.0 (2)
N1–Pd1–N2	80.3 (1)	80.3 (2)

Note: (i) Okabe *et al.* (2004).

All H atoms were located in difference Fourier maps and then repositioned in idealized locations and treated as riding, with C–H = 0.93 Å and *U*<sub>iso</sub>(H) = 1.2*U*<sub>eq</sub>(carrier).

Data collection: MSC/AFC Diffractometer Control Software (Molecular Structure Corporation, 1992); cell refinement: MSC/AFC Diffractometer Control Software; data reduction: *TEXSAN* (Molecular Structure Corporation, 2000); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *TEXSAN* (Molecular Structure Corporation, 2000).

## References

- Afrasiabi, Z., Sinn, E., Chen, J., Ma, Y., Rheingold, A. L., Zakharov, L. N., Rath, N. & Radhye, S. (2004). *Inorg. Chim. Acta*, **357**, 271–278.  
 Altomare, A., Burla, M. C., Camalli, M., Casciaro, G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.  
 Corbi, P., Massabni, A. C., Moreira, A. G., Medrano, F. J., Jasiulionis, M. G. & Costa-Neto, M. (2005). *Can. J. Chem.* **83**, 104–109.  
 Cusumano, M. & Giannetto, A. (1997). *J. Inorg. Biochem.* **65**, 137–144.  
 Giovagnini, L., Ronconi, L., Aldinucci, D., Lorenzon, D., Sitran, S. & Fregona, D. (2005). *J. Med. Chem.* **48**, 1588–1595.  
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.  
 Mansuri-Torshizi, H., Ghadimy, S. & Akbarzadeh, N. (2001). *Chem. Pharm. Bull.* **49**, 1517–1520.  
 Molecular Structure Corporation (1992). *MSC/AFC Diffractometer Control Software*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.  
 Molecular Structure Corporation. (2000). *TEXSAN*. Version 1.11. MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.  
 Muranishi, Y. & Okabe, N. (2004). *Acta Cryst.* **C60**, m47–m50.

- Neidle, S., Pearl, L. & Skelly, J. V. (1987). *Biochem. J.* **243**, 1–13.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Okabe, N., Aziyama, T. & Odoko, M. (2005). *Acta Cryst.* **E61**, m1943–m1945.
- Okabe, N., Hagihara, K., Odoko, M. & Muranishi, Y. (2004). *Acta Cryst.* **C60**, m150–m152.
- Okabe, N., Muranishi, Y. & Ajiyama, T. (2003). *Acta Cryst.* **E59**, m936–m938.
- Padhye, S., Afrasiabi, Z., Sinn, E., Fok, J., Mehta, K. & Rath, N. (2005). *Inorg. Chem.* **44**, 1154–1156.
- Rebolledo, A. P., Vieites, M., Gambino, D., Piro, O. E., Castellano, E. E., Zani, C. L., Souza-Fagundes, E. M., Teixeira, L. R., Batista, A. A. & Beraldo, H. (2005). *J. Inorg. Biochem.* **99**, 698–706.
- Shehata, M. (2001). *Transition Met. Chem.* **26**, 198–204.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Tercero, J. M., Matilla, A., Sanjuan, M. A., Moreno, C. F., Martin, J. D. & Walmsley, J. A. (2003). *Inorg. Chim. Acta*, **342**, 77–87.